Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology
RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.
Why Avidity is spinning off Atrium Therapeutics before the Novartis acquisition closes
Avidity Biosciences sets spin-off record date for Atrium ahead of Novartis deal. Find out what this carve-out reveals about RNA platform risk and M&A strategy.
Allergy relief shake-up: Dr. Reddy’s launches generic Pataday 0.7% eye drops
Dr. Reddy’s launches first U.S. generic of Pataday 0.7% eye drops. Find out what this means for the OTC allergy market and Novartis’s branded edge.
Can a global trials map help fix spondyloarthritis’s fragmented development landscape?
Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.
Oral complement therapy for myasthenia gravis? Novartis’ iptacopan enters the neurology arena
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.